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Cerebrospinal fluid administration of recombinant adeno-
associated viral (rAAV) vectors has been demonstrated to 
be effective in delivering therapeutic genes to the central 
nervous system (CNS) in different disease animal models. 
However, a quantitative and qualitative analysis of trans-
duction patterns of the most promising rAAV serotypes for 
brain targeting in large animal models is missing. Here, we 
characterize distribution, transduction efficiency, and cel-
lular targeting of rAAV serotypes 1, 2, 5, 7, 9, rh.10, rh.39, 
and rh.43 delivered into the cisterna magna of wild-type 
pigs. rAAV9 showed the highest transduction efficiency 
and the widest distribution capability among the vectors 
tested. Moreover, rAAV9 robustly transduced both glia 
and neurons, including the motor neurons of the spinal 
cord. Relevant cell transduction specificity of the glia was 
observed after rAAV1 and rAAV7 delivery. rAAV7 also dis-
played a specific tropism to Purkinje cells. Evaluation of 
biochemical and hematological markers suggested that all 
rAAV serotypes tested were well tolerated. This study pro-
vides a comprehensive CNS transduction map in a useful 
preclinical large animal model enabling the selection of 
potentially clinically transferable rAAV serotypes based on 
disease specificity. Therefore, our data are instrumental 
for the clinical evaluation of these rAAV vectors in human 
neurodegenerative diseases.
Received 1 June 2015; accepted 22 November 2015; advance online  
publication 5 January 2016. doi:10.1038/mt.2015.212
INTRODUCTION
Gene transfer of recombinant adeno-associated virus (rAAVs) 
holds promises to treat neurological disorders.1 Studies on differ-
ent recombinant vector serotypes and modes of delivery to the 
central nervous system (CNS) showed that the combination of 
both rAAV serotype used and delivery routes play a key role in 
CNS transduction properties and thus in disease phenotype res-
cue outcome. However, one of the major hurdles to developing 
an effective clinical protocol for neurological disorders is the effi-
ciency of vectors to reach the specific cell types in disease-specific 
CNS subdomains.
Attempts to treat CNS defects based on parenchymal deliv-
ery of rAAV vectors demonstrated efficacious proof-of-principle 
studies. Nonetheless, clinical trials using this approach showed 
limited benefit for Batten disease, Canavan disease, aromatic 
l-amino acid deficiency, and Parkinson’s disease.2–6 One possible 
explanation for this limited success, in addition to potential local 
inflammatory responses, is that widespread distribution within 
the affected brain area from the injection site was inadequate and 
did not target relevant cell populations. The systemic delivery of 
rAAVs with the ability to efficiently cross the blood–brain bar-
rier was recently shown as an attractive means to treat diseases 
with widespread CNS involvement.7–10 However, the vector doses 
required and exposure to visceral organs may raise concerns 
related to manufacturing costs and safety, respectively. An alter-
native route to efficiently transduce the CNS is based on delivery 
of viral vectors directly into the cerebrospinal fluid (CSF). CSF 
delivery can be achieved through ventricular, lumbar, and cister-
nal administration. The main advantage of CSF-mediated delivery 
is the exposure of the virus circulating in the CSF to a large CNS 
surface area resulting in a broad distribution of delivered viral 
particles within the CNS with a relatively limited amount of vector 
required.11 CSF-mediated delivery and spreading of molecules/
virus within the CNS occurs in two steps: (i) pia mater fenestra-
tion allows access to superficial brain parenchyma (mainly com-
posed of astroglia cells: glia limitans), which is in direct contact 
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mainly mediated by perivascular CSF transport12 and (ii) uptake 
by brain cells, which depends on the specific tropism of rAAV 
serotypes.13
Therefore, the CSF delivery is an attractive administra-
tion route to develop CNS gene therapy–based approaches. 
Interestingly, proof-of-concept studies based on CSF delivery 
of rAAVs have been reported for various neurological disorders 
affecting CNS in different animal species.14–17 However, to date, 
little is known about how CSF delivery of potentially clinically 
transferable rAAV serotypes impacts transgene transduction pat-
terns in specific CNS subdomains/cell types in large preclinical 
animal models. This information is crucial for the future develop-
ment of clinical protocols for CNS diseases based on CSF delivery 
of rAAV vectors. Neurological disorders often exhibit an onset/
presentation that affects discrete, disease-specific structures of the 
brain that then spread along the entire CNS with disease progres-
sion. Therefore, in principle, a viral vector that targets the CNS 
substructure initially affected in disease manifestation would 
result in an overall therapeutic benefit, and therapy via CSF deliv-
ery may mitigate the potential for systemic toxicity.
Here, we provide a detailed side-by-side analysis of CNS 
region/cell transduction specificity of eight rAAV serotypes 
(rAAV1, 2, 5, 7, 9, rh.10, rh.39, and rh.43) selected for their 
potential CNS tropism from the large portfolio of rAAV sero-
types available.13,18 This transduction pattern has been evaluated 
together with an assessment of safety parameters CSF injection 
of the viral vectors in pigs, a large animal model that is useful 
for preclinical studies.19 These data will provide guidance and 
immediate impact for the design of future translational clinical 
studies.
RESULTS
Pattern of GFP expression in the CNS upon  
 intra-cisterna magna injection of rAAV1,  
2, 5, 7, 9, rh.10, rh.39, and rh.43 in P30 pigs
Eight rAAV serotypes (rAAV1, 2, 5, 7, 9, rh.10, rh.39, and rh.43) 
carrying genes encoding for the green fluorescent protein (GFP) 
under the control of the CMV ubiquitous promoter were injected 
in the CSF at a dose of 1.5 × 1012 GC/Kg in wild-type (WT) pigs 
at age 30 days (P30) (Supplementary Table S1). CSF administra-
tion was based on an intra-cisterna magna (ICM) protocol pre-
viously described.20 Age-matched WT pigs ICM injected with 
 phosphate-buffered saline (PBS) were used as controls.
In order to evaluate the transduction capability of the dif-
ferent rAAV serotypes, we first analyzed the GFP expression 
patterns in the CNS of injected animals. Injected pigs were sac-
rificed 1 month postinjection, and the brains were collected and 
sliced in eleven 0.5-cm-thick coronal sections covering the main 
regions of the brain and processed either for biochemical analy-
sis or for GFP immunostaining (Supplementary Figure S1). The 
cervical region of the spinal cord was also collected (as slice S12) 
and analyzed in order to evaluate the transduction of rAAV vec-
tors in the CNS regions localized posteriorly to the injection site 
including the neurodegenerative relevant areas of motor neurons 
(Supplementary Figure S1).
GFP immunohistochemical (IHC) analysis was performed 
on frozen sections cut from selected CNS coronal slices derived 
from both rAAV-injected and control PBS-injected pigs. Frontal 
and parietal cerebral cortex (from slices S4 and S5, respectively), 
hippocampus (from slice S8), cerebellum (from slice S11), basal 
ganglia (from slice, S4 and S5), and cervical tract of the spinal 
Figure 1 IHC analysis of GFP distribution pattern in main representative areas of pig brain upon ICM delivery of rAAV1, 2, 5, 7, 9, rh.10, rh.39, 
and rh.43. GFP expression in the brain of rAAV-injected pigs was evaluated 1 month after injection by IHC analysis in four representative 40-μm coro-
nal cryosections (slice S4, S5, S8, and S11). The ×0.3/×0.4 pictures are scanned images (see Materials and Methods). Enlarged images (×4) from each 
slice showed transduction in layers I–IV of frontal cerebral cortex (slice S4), glia limitans (GL) of parietal cerebral cortex (slice S5), dentate gyrus (DG), 
and CA3 areas of hippocampus (slice S8) and cerebellum (Cb) (slice S11). Arrows indicated Purkinje cells. Bars for ×0.3 and ×0.4 images = 4 mm. Bar 
of enlarged images (×4) = 200 μm.
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cord (from slice S12) were analyzed (Supplementary Figure S1). 
The GFP signal was distributed in several CNS regions in pigs that 
were injected with rAAV9, as seen in Figure 1. In the cerebral cor-
tex, the GFP expression was evident in the layers I–IV, particularly 
in the glia limitans of layer I (Figure 1). Cerebellum also appeared 
transduced in rAAV9-injected pigs, with GFP signal observed 
in the Purkinje cells (Figure  1). rAAV9 vectors penetrated into 
the brain parenchyma also transducing the brain stem and basal 
ganglia, with GFP signal present in the accumbens and putamen 
(Supplementary Figure S2). Transduction was also evident in the 
dentate gyrus and CA3 areas of hippocampus (Figure 1).
IHC analysis of rAAV1-injected pig brains showed that the 
first layer of the cerebral cortex was transduced with preferential 
localization of the GFP signal in the glia limitans (Figure 1 and 
Supplementary Figure S2). GFP expression was also observed in 
the Purkinje cell layer of the cerebellum and in the hippocampus 
(dentate gyrus and CA3; Figure 1). rAAV7 showed a distribution 
pattern similar to that observed for rAAV1, with higher trans-
duction of Purkinje cell layer compared with the rAAV1 serotype 
(Figure 1 and Supplementary Figure S2). The glia limitans of the 
cerebral cortex and the Purkinje cells of the cerebellum appeared 
transduced also by the rAAV2 (Figure 1 and Supplementary Figure 
S2). The rAAV5 showed few GFP-positive cells in the layers I–IV of 
the cerebral cortex (Figure 1 and Supplementary Figure S2). GFP 
transduction was observed in the Purkinje cell layer of animals 
injected with rAAVrh.10, rAAVrh.39, and rAAVrh.43, while only 
a few GFP signal mainly localized to the layer I was detected in 
the cerebral cortex of these animals (Figure 1 and Supplementary 
Figure S2). rAAVrh.39-injected pigs also displayed a few GFP sig-
nal in dentate gyrus and CA3 areas of hippocampus (Figure 1). 
IHC analysis of the cervical region of the spinal cord showed that 
rAAV9 was able to transduce both neurons of lamina IX and fibers 
in the ventral column and fibers of gracile and cuneate fasciculi in 
the dorsal column (Figure 2). Both rAAV1 and rAAV7 displayed 
an astroglial transduction pattern in the spinal cord; however, the 
GFP signal was stronger in rAAV1-injected animals compared with 
rAAV7-injected animals (Figure 2). In the spinal cord, rAAV5 and 
rAAVrh.43 showed a weak GFP expression, which was localized 
in the gray matter of the ventral horn in rAAV5-injected animals 
and in the glia limitans of the ventral region in rAAVrh.43-injected 
animals (Figure  2). All  remaining rAAV serotypes analyzed did 
not exhibit any detectable GFP signal in the spinal cord (Figure 2).
Levels of GFP expression in CNS regions upon ICM 
injection of rAAV1, 2, 5, 7, 9, rh.10, rh.39, and rh.43 
in P30 pigs
GFP expression levels in brain and spinal cord were quantified by 
western blotting experiments on 20 selected CNS areas of interest, 
which were dissected from coronal slices in both rAAV-injected 
and control PBS-injected pigs (Supplementary Figure  S1). 
As seen in Figure 3, P30 injected pigs showed a GFP distribution 
pattern that overall correlated with the IHC data confirming the 
wide distribution of the rAAV9 serotype and underlining the spe-
cific distribution pattern of the other rAAV serotypes analyzed. 
However, the quantitative analysis allowed us to evaluate not 
only the distribution pattern of GFP but also the intensity of GFP 
expression in specific CNS regions of injected pigs.
Cerebral cortex. The cerebral cortex of rAAV9-injected pigs 
exhibited the highest intensity of GFP expression (Figure  3). 
rAAV1, rAAV5, and rAAV7 also showed relevant GFP protein 
levels in the cerebral cortex, with rAAV1 and rAAV7 displaying 
higher expression levels compared to rAAV5 (Figure 3).
Hippocampus. rAAV9 displayed the highest GFP expression lev-
els in the hippocampus, followed by rAAV1, rAAV5, and rAAV7 
serotypes (Figure 3). No detectable GFP expression was observed 
for all the other rAAV serotypes tested (Figure 3).
Midbrain and basal ganglia. The colliculi (superior and infe-
rior) and the substantia nigra were transduced with the  highest 
GFP  expression intensity by the rAAV9 serotype (Figure  3). 
Quantitation of GFP protein levels in the substantia nigra showed 
higher GFP expression in rAAV5-injected animals compared to 
Figure 2 IHC analysis of GFP distribution pattern in spinal cord of 
rAAV-injected pigs. IHC GFP staining on coronal cryosections (40 μm) of 
spinal cord cervical region from rAAV-injected pigs. The ×0.8 pictures are 
scanned images (see Materials and Methods). The black dashed lines indi-
cate the butterfly shape of gray matter of the spinal cord. Magnification 
images (×10) show the ventral column (VC), the lamina IX (L-IX) of the 
ventral horn, and the dorsal column (DC) of the spinal cord. Arrows in 
the panels of rAAV9-injected pigs indicate fiber transduction in the ventral 
columns, motor neurons transduction in the L-IX, and transduction of 
gracile and cuneate fasciculi fibers in the dorsal column. Ventral (V) and 
dorsal (D) sides of the spinal cord are shown in the ×0.8 scanned images. 
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that observed in rAAV1- and rAAV7-injected animals (Figure 3). 
Low GFP protein levels were detected in the colliculi of pigs 
 injected with rAAV1 serotype (Figure  3). rAAV9 exhibited the 
highest intensity of GFP expression in basal ganglia region followed 
by rAAV5, rAAV7, and rAAV1 (Figure 3). All other serotypes did 
not show detectable GFP expression in the midbrain and basal gan-
glia areas (Figure 3).
Cerebellum. The rAAV9 and rAAV7 serotypes showed similar 
levels of GFP expression in the cerebellum, and these protein levels 
were the highest among all rAAV serotypes analyzed (Figure 3). 
Lower levels of cerebellar GFP expression were displayed by 
the rAAVrh.39, rAAVrh.10, and rAAV1 serotypes (Figure  3). 
The GFP expression levels were very low or undetectable in the 
cerebellum of rAAV2-, rAAV5-, and  rAAVrh.43-injected pigs 
(Figure 3).
Spinal cord. rAAV9 displayed the highest GFP protein levels 
in the spinal cord, followed by rAAV1, rAAV7, and rAAVrh.39 
(Figure 3). All other serotypes did not show detectable GFP ex-
pression in the spinal cord region (Figure 3).
In order to further characterize the GFP transduction pat-
tern, we quantified delivered rAAV genomes in different CNS 
areas of injected pigs by quantitative polymerase chain reaction. 
High copy numbers of rAAV genomes were observed in the CNS 
regions in which strong GFP expression was observed, while neg-
ligible values of genome copy numbers were observed in the CNS 
regions with low/absent GFP expression, thus supporting the GFP 
expression profiles obtained by both IHC and western blotting 
experiments (Supplementary Figure S3).
Cell type transduction upon ICM injection of rAAV 1, 
2, 5, 7, 9, rh.10, rh.39, and rh.43 in P30 pigs
In order to precisely evaluate the specific cell types transduced 
by the different rAAV serotypes analyzed, we co-labeled the CNS 
coronal sections from rAAV-injected pigs with anti-GFP and anti-
bodies for cell-specific markers of glial and neuronal cells.
Cerebral cortex. Analysis of parietal cerebral cortex (layers 
I–IV from slice S6) revealed that ~16% of cells were GFP-positive 
in rAAV9-injected pigs, ~2–3% of cells were GFP-positive in 
rAAV1-, rAAV2-, and rAAV7-injected pigs, while less than 1% 
of GFP-positive cells were found for all other serotypes (Figure 4 
and Table 1). In rAAV1-, rAAV2-, and rAAV7-injected animals 
GFP-expressing cells almost completely co-localized with either 
GFAP or S100β astroglial markers in the layer I of cerebral cor-
tex (GFAP and S100β stain, respectively, fibrous and protoplasmic 
astrocytes), while few/no GFP-positive cells co-localizing with the 
microglial marker Iba1 or the neuronal marker NeuN were found, 
thus indicating a predominant transduction of cerebral cortical as-
trocytes for rAAV1-, rAAV2-, and rAAV7 serotypes (Figure 4). In 
rAAV9-injected pigs, ~26% of GFP-containing cells were GFAP-
positive (mostly in the glia limitans), ~41% were S100β-positive, 
~12% were Iba1-positive, and ~25% were  NeuN-positive, thus in-
dicating the capability of this serotype to efficiently transduce both 
neurons and different types of glial cells in this region (Figure 4 
Figure 3 GFP expression levels in representative areas of the CNS of rAAV-injected pigs. Western blotting analysis with anti-GFP antibody 
performed on rAAV-injected pigs. Indicated areas were taken from the rostral to the caudal part of pig CNS (see Materials and Methods and 
Supplementary Figure S1 for details). The GFP protein levels were quantified in dissected areas by densitometric analysis of GFP signals. For the 
cerebral cortex, we analyzed frontal (from slice S1 and S2), parietal (from slice S5), and occipital (from slice S8–S10) regions. Values were normal-
ized to both actin and purified GFP protein (70 ng loaded on sodium dodecyl sulfate gels) and expressed as arbitrary units (a.u., see Materials and 
Methods for details). Three animals for each serotype were analyzed. Bars represent means ± SEM from three samples (one sample for each animal).
Frontal cortex




















rAAV1 rAAV2 rAAV5 rAAV7 rAAV9
GFP transduction potency (A.U. GFP expressed/GFP purified/actin)
rAAVrh.10 rAAVrh.39 rAAVrh.43
4 www.moleculartherapy.org 
© The American Society of Gene & Cell Therapy
CNS Transduction Map by CSF Delivery of rAAVs
and Table 1). In the cerebral cortex of pigs injected with all other 
rAAV serotypes, the few GFP-positive cells found mostly co-local-
ized with astroglial markers in the  layer I (Figure 4).
Hippocampus. Analysis of the dentate gyrus and CA3 areas of 
hippocampus in rAAV9-injected pigs revealed the presence of 
several GFP-expressing cells, which, as in the cerebral cortex, 
 reflected both neuronal and astroglial cells transduction (Figure 5, 
Supplementary Figure S4, and Table 1). In the dentate gyrus area, 
GFP-positive cells co-localized with NeuN (~15%), GFAP (~43%), 
S100β (~45%), and Iba1 (~11%) markers (Figure 5 and Table 1). 
GFP-positive cells co-localizing with NeuN, GFAP, and S100β 
markers were also observed in the hippocampus (dentate gyrus 
and CA3) of rAAV1-injected pigs (Figure  5, Supplementary 
Figure S4, and Table  1). Few GFP-positive cells co-localizing 
with astroglial and neuronal markers were observed in rAAV7- 
and rAAVrh.39-injcted pigs, while negligible  GFP-positive cells 
were found in pigs injected with all other serotypes (Figure  5, 
Supplementary Figure S4, and Table 1).
Basal ganglia. In the stria terminalis and putamen areas of 
basal ganglia, only rAAV9-injected animals displayed detect-
able GFP-positive cells (Figure  6a and Table  1). Confocal im-
ages of stria terminalis showed that these GFP-expressing cells 
 co-localized with the oligodendroglial marker OLIG2 (Figure 6a). 
Remarkably, analysis of this region also showed the presence of 
some  GFP-positive signal, which, although did not co-localize 
with astroglial or neuronal markers, narrowed several projec-
tions, thus suggesting transduction of neuronal bodies resident in 
other brain regions that circuit with stria terminalis (Figure 6a).
Cerebellum. In the cerebellum, several GFP-positive cells were 
observed in rAAV7- and rAAV9-injected pigs (respectively ~12 
and ~15%), lower numbers of GFP-expressing cells were found 
in rAAVrh.10, rAAVrh.39-, rAAV2-, and rAAV1-injected pigs, 
while few/negligible GFP-positive cells were found for all other 
serotypes (Figure 6b and Table 1). Co-localization analysis with 
Calbindin marker revealed that these values reflected an efficient 
transduction of Purkinje cells (Figure 6b and Table 1). GFP co-lo-
calization with either Iba1 or astroglial markers were also found in 
both rAAV9- and rAAV7-injected pigs (Figure 6b and Table 1).
Spinal cord. In the spinal cord, several GFP-expressing cells 
were observed in rAAV9-injected pigs (Figure 7 and Table 1). 
In the ventral horn, GFP-positive cells displayed a predomi-
nant co-localization with NeuN marker (Figure 7 and Table 1). 
A few GFP signal co-localizing with NeuN marker was observed 
in both rAAV1- and rAAV5-injected pigs, while no other 
sero type showed detectable GFP-positive cells in this region 
(Figure  7 and Table  1). The use of choline acetyltransferase 
(ChAT) marker revealed that NeuN-positive GFP-expressing 
cells were mostly motor neurons in rAAV9-injected animals 
(Figure 7 and Table 1). The other serotypes tested were nega-
tive for ChAT co-staining, including rAAV5, thus indicating 
that the NeuN-positive  GFP-expressing cells in the spinal cord 
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Evaluation of toxicity and immune-responses after 
ICM injection of rAAV 1, 2, 5, 7, 9, rh.10, rh.39, and 
rh.43 in P30 pigs
We then evaluated the presence of a humoral immune response in 
treated animals. Serum and CSF were collected and screened before 
and 1 month after injection in order to determine the presence of 
neutralizing antibodies (NAbs) against the rAAV capsids. None 
of pigs analyzed showed preexisting NAbs either in serum or in 
CSF (Supplementary Table S2). At the time of sacrifice, no NAbs 
were observed in the serum or CSF of rAAV9-, rAAVrh39-, and 
rAAVrh43-injected pigs (Supplementary Table S2). In contrast, 
all animals injected with rAAV2 exhibited NAbs in both serum 
Figure 4 Cell type tropism of rAAV serotypes in the cerebral cortex of injected pigs. Epi-fluorescent images (×10) showed GFP-expressing cells 
co-stained with DAPI in the parietal cerebral cortex (layers I–IV from slice 6) of rAAV-injected pigs. Confocal images (×40) showed GFP co-localization 
with neuronal (NeuN), astroglial (GFAP, S100β), and microglial (Iba1) markers in the same region. Bar for epifluorescent images = 75 μm. Bar for 
confocal images = 50 μm.
Epi (×10) Epi (×10)Confocal (×40) Confocal (×40)
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and CSF. Results for the remaining rAAV serotypes were variable 
with some, but not all, animals displaying NAbs in serum and CSF 
(Supplementary Table S2).
In order to assess early safety signals, panels of biochemi-
cal and hematological markers potentially indicative of renal 
or hepatic damage/failure, as well as inflammation, were 
evaluated, and piglet weight was determined on the day of 
the injection and at sacrifice to evaluate normal physiologi-
cal development. No significant differences were detected 
between rAAV-injected animals and controls for markers 
tested before injection and at the end of the experimental pro-
tocol (Supplementary Table  S3). The change in the variables 
that were observed in pigs (either controls or rAAV-injected) 
when comparing pre- and post-injection time is easily related to 
Figure 5 Cell type tropism of rAAV serotypes in the hippocampus of injected pigs. Epi-fluorescent images (×10) showed GFP-expressing cells 
 co-stained with DAPI in the dentate gyrus of hippocampus of rAAV-injected pigs. Confocal images (×40) showed GFP co-localization with NeuN, 
S100β, and GFAP markers in the same region. Bar for epifluorescent images: 75 μm. Bar for confocal images: 50 μm.
Epi (×10) Epi (×10)Confocal (×40) Confocal (×40)
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the physiological developmental stages of the pig.21 Moreover, 
weight increase in rAAV-injected pigs was about 75%, similar 
to that observed in control PBS-injected pigs (Supplementary 
Table S1). No differences in behavioral patterns were observed 
between rAAV- and PBS-injected pigs. None of the animals 
showed pain-related postures or signs. A small number of ani-
mals (six pigs injected with rAAV5 and rAAV9) exhibited a very 
mild ataxia that resolved within 12 hours post-injection. In the 
following days, they were able to eat, drink, and interact nor-
mally, without any signs of stress.
Overall, these data suggest that the ICM procedure and rAAV 
administration were safe and well tolerated over a 1-month period 
without a significant impact on a number of key physiological 
parameters.
DISCUSSION
In this study, we generated a comprehensive and detailed CNS 
transduction map for eight recombinant rAAV viral vector sero-
types administered via CSF delivery in a large animal model, Sus 
scrofa. We evaluated the transduction efficiency in 20 regions 
covering the entire brain from the prefrontal to the occipital 
region, including the spinal cord. This analysis encompassed the 
quantification of rAAV-delivered GFP protein levels and the char-
acterization of both the CNS distribution and cellular-specific 
transduction profile for each of the serotypes tested (summarized 
in Supplementary Table S4). Importantly, since CSF-mediated 
transport provides CSF-circulating molecules access to both 
superficial and deeper regions of the brain parenchyma,12 the 
observed CNS distribution of rAAV vectors reflected the intrinsic 
capability of rAAV serotypes to transduce specific brain regions 
when taken up by different cells (i.e., tropism).
Overall, our data showed a significant differential tropism of 
the rAAV serotypes tested, as illustrated by the GFP expression 
patterns observed. Moreover, the present study provides impor-
tant information on both regional and cellular specificity of the 
transduction patterns that suggest potential therapeutic advan-
tages/disadvantages when considering rAAV-based treatments 
for both cell-autonomous and non–cell-autonomous CNS disor-
ders. Injection of rAAV9 resulted in the widest GFP expression 
along the entire CNS, showing efficient and widespread trans-
duction of neurons and glial cells of different layers of cerebral 
cortex, basal ganglia, midbrain, and brain stem areas including 
motor neurons of the spinal cord. These data are consistent with 
the CNS transduction pattern of rAAV9 described by us and other 
Figure 6 Cell type tropism of rAAV serotypes in the stria terminalis and cerebellum of injected pigs. Epi-fluorescent images (×10) showed 
 GFP-expressing cells co-stained with DAPI in the (a) stria terminalis and in the (b) cerebellum of rAAV-injected pigs. Confocal images (×40) showed 
GFP co-localization with NeuN, OLIG2, and S100β markers in the (a) stria terminalis and with (b) Calbindin and S100β in the cerebellum of 
 rAAV-injected pigs. Bar for epifluorescent images = 75 μm. Bar for confocal images = 50 μm.
rAAV1 rAAV2 rAAV5 rAAV7 rAAV9 rAAVrh.10 rAAVrh.39 rAAVrh.43
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groups.14–16,22–24 In contrast to the wide-transduction spectrum of 
rAAV9, the other rAAV serotypes tested displayed more promi-
nent cell-specific transduction profiles. In particular, rAAV1 and 
rAAV7 efficiently transduce the glia limitans, with rAAV7 also 
showing a specific Purkinje cell tropism. rAAVrh.10 also dis-
played a tropism to Purkinje cells, as previously reported in rats.17 
Transduction of microglial cells was observed for several rAAV 
serotypes tested including rAAV1, rAAV2, rAAV7, and rAAV9.
An important aspect of translational studies is the demonstra-
tion of safety. While the experiments herein described were not 
designed to fully investigate the potential for treatment-related 
toxicities, an effort was made to look for early safety signals. 
Beside transient ataxia post-surgery in some animals, no overt 
signs of distress were observed. Moreover, consistent with previ-
ous studies,25 we did not observe preexisting NAbs against any of 
the rAAV capsids tested while NAbs were present only for some 
serotypes (rAAV1, rAAV2, rAAV5, rAAV7, and rAAVrh.10) in a 
few injected animals (Supplementary Table S2). Nevertheless, 
it has been described that low levels of circulating NAbs do not 
interfere with CNS gene transfer after CSF delivery.14,15,26 Recently, 
Samaranch et  al.27 described antigen-presenting cell–mediated 
neuroinflammation against non-self protein (GFP). In the present 
study, we did not evaluate the presence of such an inflammatory 
response; however, its potential toxicity could be overcome by the 
use of a self-protein as reported.27 Moreover, although we observed 
a lack of immunotoxicity at 1 month after injection, we do not 
exclude that tardive immune responses (e.g.,  cell-mediated) might 
be present in treated animals after long-term analysis (>8 weeks).
The data described herein demonstrate the value of rAAV 
delivery via CSF as a mode to efficiently transduce the CNS, com-
pare, contrast, and map the tropism, transduction efficiency, and 
cell specificity of eight rAAV serotypes in a large animal model. 
Therefore, although translating these results to human should take 
into account potential differences in the tropism features of the 
AAV vectors tested, our work provides a guide to investigators 
to better match rAAV serotypes with the needs of specific neu-
rodegenerative diseases that could be potentially treated with a 
 gene-therapy approach.
MATERIALS AND METHODS
Viral vectors. rAAV vectors were produced by the TIGEM rAAV Vector 
Core by triple-plasmid transfection of HEK293 cells and were purified by 
two rounds of CsCl2 gradient centrifugation.
28 Viral vector titers (genome 
copies/ml) were determined by real-time PCR quantification using 
TaqMan (Applied Biosystems, Foster City, CA) and dot-blot analysis.28
The final titer of each preparation was calculated as the average 
between the PCR quantification and dot-blot results.
Animals, rAAV administration, and tissue collection. The study was 
conducted in accordance with the provisions of European Economic 
Community Council Directive 86/609 adopted by the Italian Government 
(DL 27/01/1992 No. 116) under the local approval of the Ethical Committee 
of the University of Bologna and under the approval of Italian Ministry of 
Health.
Figure 7 Cell type tropism of rAAV serotypes in the spinal cord of injected pigs. Epi-fluorescent scanned images (×4) showed GFP-expressing 
cells co-stained with NeuN in the spinal cord (cervical region) of rAAV-injected pigs. Confocal images (×20 and ×40) showed GFP co-localization with 
either NeuN or ChAT (marker of motor neurons) in the ventral horn of the spinal cord (cervical region). Arrows in epifluorescent ×4 images indicate 
the lamina IX area containing the motor neurons. D, dorsal horn; V, ventral horn. Bar for ×4 images = 400 μm. Bar for ×20 images = 100 μm. Bar for 
×40 images = 150 μm.
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All animal studies have been approved by the authors.
The animals enrolled were WT large White × Duroc hybrids, and the 
sex ratio between females and castrated males was ~1:1.
These animals were transferred to our facility on the day of weaning 
(28th day after birth) and housed in multiple stalls with infrared heating 
lamps. They were strictly monitored in order to rule out any pathology 
that may have affected the entire experiment.
AVV administration. All of the activities performed on the day of the injec-
tion have been thoroughly described by Romagnoli et al.20 In brief, ani-
mal received an i.m. bolus of tiletamine-zolazepam (5 mg/kg) 10 minutes 
before induction; general anesthesia was achieved using sevoflurane with 
an induction mask. After orotracheal intubation and stabilization, venous 
access for fluid therapy was achieved from an auricular vein. Blood sam-
ples (6 ml) were collected through the femoral artery.
The dorsal area of the neck was trimmed and surgically prepared, 
and the puncture of the cisterna magna was performed as previously 
described.20 One ml of CSF was collected before the injection in order to 
analyze it as a preinjection physiological standard. The dose of 1.5 × 1012 
GC/Kg of viral vector in the volume range from 0.5 to 2.8 ml was injected 
slowly to avoid a sudden increase in intracranial pressure. Piglets were 
then placed in Trendelenburg position for 2 minutes in order to help the 
injected compound to spread toward the more rostral parts of the CNS. 
Animals were then monitored until complete recovery.
During the following days, all animals were strictly monitored in 
order to rule out any possible side effect of the procedure and to evaluate 
any changes in behavior and consequentially in welfare.
Sacrifice and tissue collection. Procedures for anesthesia, venous access, 
and blood sampling were exactly the same as performed on the day of 
the injection. CSF samples were collected by puncturing the lumbar spi-
nal space rather than the cisterna magna. Percutaneous cystocentesis was 
performed to obtain sterile urine samples (3 ml). Animals were then sac-
rificed with a single bolus (0.3 ml/kg) of Tanax and total body perfusion 
with Dulbecco’s phosphate-buffered saline was started. After median ster-
notomy, the right atrium was opened and the left ventricle was infused 
with 500 ml of warm Dulbecco’s phosphate-buffered saline (+38 °C) and 
1,000 ml of cold Dulbecco’s phosphate-buffered saline (+4 °C); blood 
ejected from the right atrium was drained using a surgical aspirator.
As far as CNS samples, collected tissues were the whole brain and 
cervical region of spinal cord. Dissection was performed using the 
technique described by Wischnitzer29 modified by Prof C. Bombardi. 
Blood samples were collected using a vacuum system, and tubes with 
K3ethylenediaminetetraacetic acid anticoagulant, citrate, and clot activator 
were used. Samples were processed within 1 hour from collection and 
analyzed or stored at −80 °C until analysis.
All animals had a complete blood work (ADVIA 2120, Siemens 
Healthcare Diagnostics, Tarrytown, NY) including complete blood count 
with hematocrit value, hemoglobin concentration, erythrocyte indices, 
platelet count, white blood cell with differential white blood cell counts 
and blood smear examination, and a chemistry profile including aspartate 
transaminase, alanine transaminase, creatinine, urea, total protein, 
albumin, albumin to globulin ratio. All chemistry analyses were carried 
out on an automated chemistry analyser (Olympus AU 400, Beckman 
Coulter/Olympus, Brea, CA).
Evaluation of AAV vector copy number in the CNS. Genomic DNA was 
extracted from five selected regions of CNS using a DNeasy Blood and Tissue 
Extraction kit (Qiagen, Valencia, CA). We selected CNS regions, which were 
efficiently transduced at least by three viral vectors. DNA concentration was 
determined by using a Nanodrop. Real-time PCR was performed on 100 ng 
of genomic DNA using a LightCycler SYBR green I system (Roche, Almere, 
The Netherlands). For the amplification, the EGFP fwd (5′ AGC AGC ACG 
ACT TCT TCA ACT CC 3′) and EGFP rev (5′ CCA TGA TAT AGA CGT 
TGT GG 3′) were used. Amplification was run on a LightCycler 96 device 
(Roche) with standard cycles. A standard curve was generated, using the cor-
responding AAV vector plasmid pAAV2.1CMV-EGFP.
GFP immunoblotting. To quantify the GFP protein, 20 main regions cover-
ing the entire CNS of injected pigs were dissected and then snap-frozen 
in liquid nitrogen (see Supplementary Figure S1). Approximately 70 mg 
of each dissected region were homogenized with TissueLyser using 10 vol-
umes (700 µl) of 3× Flag lysis buffer (50 mmol/l Tris–HCl pH8, 200 mmol/l 
NaCl, 1% Triton X100, 1 mmol/l ethylenediaminetetraacetic acid, and 50 
mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and a prote-
ase inhibitor cocktail (Sigma-Aldrich, St Louis, MO). The lysates were incu-
bated in ice for 1 hour and cleared by centrifugation. Protein concentration 
was determined using the Bio-Rad colorimetric assay (Bio-Rad, Hercules, 
CA). Thirty micrograms of homogenate protein were separated on a 12% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred 
to polyvinyl difluoride membrane at 30 V over night. As control, 70 ng of 
purified GFP was loaded on sodium dodecyl sulfate gels. Anti-GFP rab-
bit polyclonal (1:1,000, NB600-308; Novus BIO, Littleton, CO) and anti-
β-actin mouse monoclonal antibodies (1:2,000, A5441, Sigma-Aldrich) 
were, respectively, used for the detection of GFP and actin proteins. The 
membranes were incubated with secondary antirabbit and antimouse anti-
bodies (1:5,000, CALBIOCHEM, San Diego, CA), and protein bands were 
visualized using UVP-ChemiDoc-It (Life Science Software, Hopkinton, 
MA). Relative band intensity was quantified by densitometric analysis using 
ImageJ software (National Institutes of Health, Bethesda, MD).
The intensity of bands corresponding to the GFP expressed in brain 
lysates was quantified by densitometric analysis. Each of these values was 
divided for both the value resulting from densitometric quantitation of 
the band corresponding to the purified GFP (which was loaded on the 
same sodium dodecyl sulfate gel in which the brain samples were loaded) 
and the value resulting from densitometric quantitation of actin. The 
resulting ratio was expressed as arbitrary units (a.u.)
Immunolabeling. IHC staining of GFP was performed on 40 μm floating 
cryosections derived from brain and spinal cord of injected pigs.
Sections were washed in PBS/Triton X-100 0.1% (wash buffer), 
incubated for 30 minutes at room temperature in 1% hydrogen peroxidase 
diluted in PBS 1× and incubated overnight at 4 °C in primary antibody 
solution: PBS 1×/ Triton X-100 0.1%, 2% horse serum, rabbit anti-GFP 
(1:1,500, NB600-308; Novus BIO). Anti-GFP was detected with MACH4 
Universal HRP-Polymer Biotin-Free Detection Polymer Detection Kit 
(BIOCARE Medical, Concord, CA). After 1 hour, we washed three times 
the sections and developed the signal with diaminobenzidine (Vectorstain 
Kit; Vector Laboratories, Burlingame, CA). Sections were then mounted 
with CV Ultra Mounting Media (Leica, Wetzlar, Germany).
To identify the cell types, we performed immunofluorescence 
experiments on 30-μm cryosections. Samples were blocked in  TBS1X-Triton 
0.3% and Donkey Serum 5% for 1 hour at room temperature and incubated 
with anti-GFP either rabbit polyclonal (1:1,000,  NB600-308; Novus BIO) 
or chicken polyclonal 9 (1:800, AB13970; Abcam, Cambridge, UK), anti-
S100β mouse monoclonal (1:800, AB66028; Abcam), anti-IBA1 rabbit 
polyclonal (1:500, 234003; Synaptic System, Gottingen, Germany), anti-
NeuN mouse monoclonal (1:400, MAB377; Millipore), anti-GFAP mouse 
monoclonal (1:200, MAB3402; Millipore, Amsterdam, the Netherlands), 
anti-Olig2 mouse monoclonal (1:200, MABN50; Millipore), and anti-CHAT 
goat poyclonal (1:100, AB144P; Millipore) to, respectively, identify GFP 
protein, neurons, astrocytes, oligodendrocytes, and motor neurons. After 
overnight incubation with primary antibody, sections were washed in PBS 
1× and incubated with Alexa Fluor 488-conjugated donkey antirabbit (1:500; 
Invitrogen, Carlsbad, CA), Alexa Fluor 594-conjugated donkey anti-mouse 
(1:500; Invitrogen), and Alexa Fluor 594-conjugated donkey anti-goat (1:500; 
Invitrogen). Rinsed sections were mounted with VECTASHIELD mounting 
medium with 4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI) 
(Vinci-Biochem, Florence, Italy) and analyzed by either epi-fluorescent and 
confocal microscopy.
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GFP quantitation (% of GFP-positive cells) in immunofluorescence 
experiments. We quantified the GFP immunofluorescence signal in the 
CNS of injected pigs in five main CNS regions (parietal cerebral cor-
tex from slice S6, dentate gyrus of hippocampus from slice S8, putamen 
from slice S5, cerebellum from slice S11, and lamina IX of the cervical 
tract of spinal cord (slice S12). One square millimeter area of four dif-
ferent sections (30 μm) stained with DAPI and co-labeled with GFP, and 
the specific cell type markers (NeuN, Calbindin, ChAT, GFAP, S100β, 
Iba1, or OLIG2) were scanned in z-stack using Zeiss LSM 710 micro-
scope equipped with a Zeiss confocal-scanning laser using a 40× objec-
tive (Zeiss, Oberkochen, Germany). The exposure time used to acquire 
all images was identical. The co-localization analysis was performed by 
the microscope ZEISS 2008 program. Total number of DAPI- and GFP-
positive signals were counted using the cell-counter program (ImageJ 
software) with a fixed threshold. Total GFP cell counts present in the 
1 mm2 area analyzed were then expressed as percentage of total cells 
(DAPI positive) expressing the GFP (%GFP-positive cells). For CNS 
regions in which the %GFP-positive cells was >10%, NeuN-, Calbindin-, 
ChAT-, GFAP-, S100β-, Iba1-, or OLIG2-positive cells were also counted 
and expressed as percentage of GFP-positive cells expressing the specific 
cell type marker.
Microscopy. 3,3’-Diaminobenzidine-processed brain and spinal cord 
sections were digitized using a Scan-Scope slide scanner (Leica scn400). 
Virtual slides were viewed using Leica digital image hub, and images were 
generated using the same software. Immunofluorescence images of the 
entire cervical region of the spinal cord were digitized using a Scan-Scope 
slide scanner (Leica scn400). Fluorescence images at ×10 magnification 
were visualized by  epi-fluorescence microscope. Confocal microscopy was 
performed with a Zeiss LSM 710 confocal microscope equipped with a 
Zeiss  confocal-scanning laser using 40× objective.
Neutralizing antibody assay. The presence of NAbs to rAAV capsid was 
assessed, on serum and CSF collected at the day of injection and 1 month 
after injection, as previously described.30
Data analysis. Biochemical and hematological results among groups 
were compared using nonparametric statistics (Mann–Whitney U-test, 
Kruskal–Wallis ANOVA, and Friedman test for paired data). Data are 
expressed as mean ± 1 SEM (n = 3). A P value of <0.05 was considered to 
be statistically significant.
SUPPLEMENTARY MATERIAL
Figure S1. Scheme of pig brain and spinal cord dissection.
Figure S2. IHC analysis of GFP distribution pattern in basal ganglia of 
pig brain upon ICM delivery of rAAV1, 2, 5, 7, 9, rh.10, rh.39, and rh.43.
Figure S3. Distribution of rAAV vector genomes following ICM injec-
tion in pig.
Figure S4. Cell type tropism of rAAV serotypes in the CA3 area of the 
hippocampus of injected pigs.
Table S1. Summary of injections in P30 pigs.
Table S2. Neutralizing anti-AAV antibody levels.
Table S3. Biochemical and hematological parameters.
Table S4. Summary of GFP transduction.
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